Visualizing fungal infections in living mice using bioluminescent pathogenic Candida albicans strains transformed with the firefly luciferase gene.

Animal studies with Candida albicans have provided models for understanding fungal virulence and antifungal drug development. To non-invasively monitor long-term Candida murine infections, clinical isolates were stably transformed with a codon-optimized luciferase gene to constitutively express luciferase. Chronic systemic infections were established in mice with engineered strains, and bioluminescent signals were apparent from kidneys by non-invasive imaging using charged-coupled device cameras. These infections were established in immune-competent mice, and bioluminescence was detectable in animals that showed no physiological consequence of infection, as well as those visually succumbing to the disease. Similarly, bioluminescence was measured from the vaginal tissue of mice infected vaginally. Fungal loads determined by plating vaginal lavages showed a similar pattern to the bioluminescent signals measured, and fungal infection could be detected in animals for over 30 days post infection by both modalities. The effect of the antifungal drug miconazole was tested in this model, and clearance in animals was apparent by both direct imaging and fungal load determination. The use of bioluminescence to monitor these and other models of Candida infections will greatly speed up the analysis of drug development studies, both in ease of visualizing infections and decreasing numbers of animals required to run such studies.

[1]  L. Peterson,et al.  Thirteen-Year Evolution of Azole Resistance in Yeast Isolates and Prevalence of Resistant Strains Carried by Cancer Patients at a Large Medical Center , 1998, Antimicrobial Agents and Chemotherapy.

[2]  Xi Chen,et al.  Cloning and Functional Analysis of ALS Family Genes from Candida albicans. , 2000, Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica.

[3]  T. Doyle,et al.  Expression of firefly luciferase in Candida albicans and its use in the selection of stable transformants. , 2006, Microbial pathogenesis.

[4]  R. Weissleder,et al.  In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.

[5]  D. Irwin,et al.  Isogenic strain construction and gene mapping in Candida albicans. , 1993, Genetics.

[6]  P. Sundstrom,et al.  Molecular cloning of cDNA and analysis of protein secondary structure of Candida albicans enolase, an abundant, immunodominant glycolytic enzyme , 1992, Journal of bacteriology.

[7]  S. Piscitelli,et al.  Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. , 1998, Advances in pharmacology.

[8]  J. Sobel Pathogenesis and Epidemiology of Vulvovaginal Candidiasis , 1988, Annals of the New York Academy of Sciences.

[9]  G. Bodey,et al.  The emergence of fungi as major hospital pathogens. , 1988, The Journal of hospital infection.

[10]  N. Georgopapadakou,et al.  Human mycoses: drugs and targets for emerging pathogens. , 1994, Science.

[11]  Kevin Francis,et al.  Direct Continuous Method for Monitoring Biofilm Infection in a Mouse Model , 2003, Infection and Immunity.

[12]  J. Mullins,et al.  Photonic detection of bacterial pathogens in living hosts , 1995, Molecular microbiology.

[13]  G. Bodey Topical and systemic antifungal agents. , 1988, The Medical clinics of North America.

[14]  C Scully,et al.  Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. , 1995, The Journal of antimicrobial chemotherapy.

[15]  B. Rice,et al.  In vivo imaging of light-emitting probes. , 2001, Journal of biomedical optics.

[16]  L. Hoyer,et al.  The ALS gene family of Candida albicans. , 2001, Trends in microbiology.

[17]  A. Johnson,et al.  Control of filament formation in Candida albicans by the transcriptional repressor TUP1. , 1997, Science.

[18]  J. Sobel,et al.  Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison toC. albicans , 1999, Clinical Microbiology Reviews.

[19]  Kevin P. Francis,et al.  Monitoring Bioluminescent Staphylococcus aureusInfections in Living Mice Using a Novel luxABCDEConstruct , 2000, Infection and Immunity.

[20]  P. Yeni,et al.  Rodent Models of Candida Sepsis , 1999 .

[21]  R. Weissleder,et al.  Molecular imaging in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[22]  L. Hoyer,et al.  Detection of Als Proteins on the Cell Wall ofCandida albicans in Murine Tissues , 1999, Infection and Immunity.

[23]  J. Staab,et al.  Genetic organization and sequence analysis of the hypha‐specific cell wall protein gene HWP1 of Candida albicans , 1998, Yeast.

[24]  D. Smith,et al.  Fluconazole resistant candida in AIDS. , 1991, The Journal of infection.

[25]  R. Sidwell,et al.  Handbook of Animal Models of Infection , 1999 .

[26]  Yohei Miyagi,et al.  Metastatic patterns of lung cancer visualized live and in process by green fluorescence protein expression , 1997, Clinical & Experimental Metastasis.

[27]  D. Stevenson,et al.  In Vivo Patterns of Heme Oxygenase-1 Transcription , 2001, Journal of Perinatology.

[28]  J. Sobel,et al.  Torulopsis glabrata vaginitis: Clinical aspects and susceptibility to antifungal agents , 1990, Obstetrics and gynecology.

[29]  J. Sobel,et al.  Murine Models of Candida Vaginal Infections , 1999 .

[30]  C. Beck-Sague,et al.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.

[31]  A. Cassone,et al.  Rat Model of Candida Vaginal Infection , 1999 .

[32]  C. Contag,et al.  Use of reporter genes for optical measurements of neoplastic disease in vivo. , 2000, Neoplasia.

[33]  W. Semmler,et al.  Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands , 2001, Nature Biotechnology.

[34]  H. Shimada,et al.  Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. C. White,et al.  Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.

[36]  J. Graybill The future of antifungal therapy. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  Z. A. Evans,et al.  Organ Localization in Mice Challenged with a Typical Candida albicans Strain and a Pseudohyphal Variant 1 , 1977, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[38]  D. McClish,et al.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  Jann Hau,et al.  Handbook of Laboratory Animal Science , 2004 .

[40]  David K. Stevenson,et al.  Rapid in vivo functional analysis of transgenes in mice using whole body imaging of luciferase expression , 2001, Transgenic Research.

[41]  J. Staab,et al.  Reevaluation of the Role of HWP1 in Systemic Candidiasis by Use of Candida albicans Strains with Selectable Marker URA3 Targeted to the ENO1 Locus , 2002, Infection and Immunity.

[42]  S. Gambhir,et al.  Optical imaging of Renilla luciferase reporter gene expression in living mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.